These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17668882)

  • 1. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease.
    Montano-Loza AJ; Carpenter HA; Czaja AJ
    Hepatology; 2007 Oct; 46(4):1138-45. PubMed ID: 17668882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis.
    Czaja AJ
    J Hepatol; 2009 Jul; 51(1):161-7. PubMed ID: 19446908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis.
    Yeoman AD; Westbrook RH; Zen Y; Maninchedda P; Portmann BC; Devlin J; O'Grady JG; Harrison PM; Heneghan MA
    Hepatology; 2011 Mar; 53(3):926-34. PubMed ID: 21374663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse.
    Montano-Loza AJ; Carpenter HA; Czaja AJ
    Am J Gastroenterol; 2007 May; 102(5):1005-12. PubMed ID: 17319926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmune hepatitis in Italy: the Bologna experience.
    Muratori P; Granito A; Quarneti C; Ferri S; Menichella R; Cassani F; Pappas G; Bianchi FB; Lenzi M; Muratori L
    J Hepatol; 2009 Jun; 50(6):1210-8. PubMed ID: 19395113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis.
    Ichai P; Duclos-Vallée JC; Guettier C; Hamida SB; Antonini T; Delvart V; Saliba F; Azoulay D; Castaing D; Samuel D
    Liver Transpl; 2007 Jul; 13(7):996-1003. PubMed ID: 17370335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis.
    Czaja AJ; Strettell MD; Thomson LJ; Santrach PJ; Moore SB; Donaldson PT; Williams R
    Hepatology; 1997 Feb; 25(2):317-23. PubMed ID: 9021941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of HLA DRB103-DRB104 in type 1 autoimmune hepatitis.
    Montano-Loza AJ; Carpenter HA; Czaja AJ
    Liver Int; 2006 Dec; 26(10):1201-8. PubMed ID: 17105585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and HLA phenotypes of type 1 autoimmune hepatitis in North American patients outside DR3 and DR4.
    Czaja AJ; Carpenter HA; Moore SB
    Liver Int; 2006 Jun; 26(5):552-8. PubMed ID: 16761999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable outcomes of autoimmune hepatitis in a community clinic setting.
    Seo S; Toutounjian R; Conrad A; Blatt L; Tong MJ
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1410-4. PubMed ID: 18373564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis.
    Czaja AJ; Menon KV; Carpenter HA
    Hepatology; 2002 Apr; 35(4):890-7. PubMed ID: 11915036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and corticosteroid therapy in patients with autoimmune-hepatitis-induced liver failure.
    Zhu B; You SL; Wan ZH; Liu HL; Rong YH; Zang H; Xin SJ
    World J Gastroenterol; 2014 Jun; 20(23):7473-9. PubMed ID: 24966618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis.
    Montano-Loza AJ; Shums Z; Norman GL; Czaja AJ
    Liver Int; 2012 Jan; 32(1):85-92. PubMed ID: 21745277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis.
    Czaja AJ; Donaldson PT
    Am J Gastroenterol; 2002 Aug; 97(8):2051-7. PubMed ID: 12190176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis.
    Czaja AJ; Donaldson PT; Lohse AW
    Am J Gastroenterol; 2002 Feb; 97(2):413-9. PubMed ID: 11866281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background.
    Bittencourt PL; Farias AQ; Porta G; Cançado EL; Miura I; Pugliese R; Kalil J; Goldberg AC; Carrilho FJ
    J Clin Gastroenterol; 2008 Mar; 42(3):300-5. PubMed ID: 18223493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction value of model for end-stage liver disease scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment.
    Yu JW; Sun LJ; Zhao YH; Li SC
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1242-9. PubMed ID: 18637053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remission in autoimmune hepatitis: what is it, and can it ever be achieved?
    Al-Chalabi T; Heneghan MA
    Am J Gastroenterol; 2007 May; 102(5):1013-5. PubMed ID: 17489784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Features and consequences of untreated type 1 autoimmune hepatitis.
    Czaja AJ
    Liver Int; 2009 Jul; 29(6):816-23. PubMed ID: 19018980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis.
    Abe M; Onji M; Kawai-Ninomiya K; Michitaka K; Matsuura B; Hiasa Y; Horiike N
    Clin Gastroenterol Hepatol; 2007 Feb; 5(2):255-8. PubMed ID: 17218164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.